

August 19, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Incorporation of a Step-Down Subsidiary Company in Tashkent, Uzbekistan
Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)

Dear Sir/ Madam,

We wish to inform you that Dr Lal PathLabs FZCO, Dubai, United Arab Emirates, Wholly Owned Subsidiary of the Company, has incorporated a Company in Tashkent, Uzbekistan named “**Dr Lal PathLabs Indomed LLC**” on August 19, 2026, and has agreed to subscribe 70% of its share capital.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time is enclosed herewith as “**Annexure – A**”.

Thanking You,
Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer
Encl.: As above

Annexure-A
DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

S. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Name of the incorporated entity: Dr Lal PathLabs Indomed LLC Turnover, size: Not applicable, since it is a newly incorporated company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not Applicable, since this intimation is regarding the incorporation and agreed for subscription of the share capital of the Step-Down Subsidiary of the Company.
3	Industry to which the entity being acquired belongs	Diagnostic Services
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To strengthen the Group's presence in Tashkent, Uzbekistan.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	The subscription will be at face value
9	Percentage of shareholding / control acquired and / or number of shares acquired	70% shareholding is being subscribed by Dr Lal PathLabs FZCO, Dubai, United Arab Emirates, Wholly Owned Subsidiary of the Company.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Dr Lal PathLabs Indomed LLC, Tashkent, Uzbekistan will be engaged in business of providing diagnostics services. Date of Incorporation: August 19, 2026 Turnover: Not applicable (newly incorporated company). Country: Tashkent, Uzbekistan